Serum Golgi Protein 73 as a Noninvasive Marker of Hepatic Fibrosis in Chronic Hepatitis C Virus Infection.

Authors

Yun-Chu Chen, Yu-Ping Chang, Jenna Bedrava, Laurel Jackson, Ji-Yuh Lee, Chi-Yi Chen, Wei-Yu Kao, Chih-Lin Lin, Sheng-Shun Yang, Yu-Lueng Shih, Cheng-Yuan Peng, Fu-Jen Lee, Ming-Chang Tsai, Shang-Chin Huang, Tung-Hung Su, Tai-Chung Tseng, Chun-Jen Liu, Pei-Jer Chen, Jia-Horng Kao, Claire Chen, Chen-Hua Liu

Published in

Journal of medical virology. Volume 98. Issue 10. Pages e71183.

Abstract

The clinical utility of serum Golgi protein 73 (GP73) for evaluating hepatic fibrosis in hepatitis C virus (HCV) infection remains to be determined. We retrospectively enrolled 978 patients with serum GP73, aspartate-to-platelet ratio index (APRI), and Fibrosis-4 (FIB-4) measurements. Hepatic fibrosis was staged using vibration-controlled transient elastography (VCTE) with cutoff values of ≤ 7.0, 7.1-9.4, 9.5-12.4, and ≥ 12.5 kPa corresponding to F0-F1, F2, F3, and F4. Distributions of GP73, APRI, and FIB-4 levels across fibrosis stages were compared using Kruskal-Wallis tests. Areas under the receiver operating characteristic curves (AUROCs) were calculated and compared using DeLong tests, and optimal GP73 cutoff values were determined by maximal Youden indices. Multivariable linear regression was performed for factors associated with GP73 levels. Median GP73, APRI, and FIB-4 levels increased with advancing fibrosis stage (p < 0.001). Serum GP73 showed superior performance to APRI in discriminating ≥ F2 (AUROC 0.86 vs. 0.79, p < 0.001), ≥ F3 (0.88 vs. 0.81, p < 0.001), and F4 (0.90 vs. 0.84, p = 0.002). GP73 showed better performance than FIB-4 for ≥ F2 (0.86 vs. 0.82, p = 0.005) and comparable performance for ≥ F3 (0.88 vs. 0.87, p = 0.63) and F4 (0.90 vs. 0.89, p = 0.72). Optimal GP73 cutoff values were 122, 159, and 174 ng/mL for ≥ F2, ≥ F3, and F4. Regression analysis demonstrated a significant association between fibrosis stage and GP73 levels. In conclusion, serum GP73 is a reliable and accurate noninvasive biomarker for staging hepatic fibrosis for HCV.

PMID:
42895453
Bibliographic data and abstract were imported from PubMed on 19 Oct 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.